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Background: Patients undergoing vascular surgery procedures constitute a ‘high-risk’ group. Fatal and disabling
perioperative complications are common. Complications arise via multiple aetiological pathways. This mechanistic
redundancy limits techniques to reduce complications that target individual mechanisms, for example, anti-platelet
agents. Remote ischaemic preconditioning (RIPC) induces a protective phenotype in at-risk tissue, conferring protection
against ischaemia-reperfusion injury regardless of the trigger. RIPC is induced by repeated periods of upper limb
ischaemia-reperfusion produced using a blood pressure cuff. RIPC confers some protection against cardiac and renal
injury during major vascular surgery in proof-of-concept trials. Similar trials suggest benefit during cardiac surgery.
Several uncertainties remain in advance of a full-scale trial to evaluate clinical efficacy. We propose a feasibility trial to fully
evaluate arm-induced RIPC’s ability to confer protection in major vascular surgery, assess the incidence of a proposed
composite primary efficacy endpoint and evaluate the intervention’s acceptability to patients and staff.
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Methods/Design: Four hundred major vascular surgery patients in five Irish vascular centres will be randomised (stratified
for centre and procedure) to undergo RIPC or not immediately before surgery. RIPC will be induced using a blood
pressure cuff with four cycles of 5 minutes of ischaemia followed by 5 minutes of reperfusion immediately before the
start of operations. There is no sham intervention. Participants will undergo serum troponin measurements pre-
operatively and 1, 2, and 3 days post-operatively. Participants will undergo 12-lead electrocardiograms pre-operatively and
on the second post-operative day. Predefined complications within one year of surgery will be recorded. Patient and
staff experiences will be explored using qualitative techniques. The primary outcome measure is the proportion of
patients who develop elevated serum troponin levels in the first 3 days post-operatively. Secondary outcome measures
include length of hospital and critical care stay, unplanned critical care admissions, death, myocardial infarction, stroke,
mesenteric ischaemia and need for renal replacement therapy (within 30 days of surgery).
Discussion: RIPC is novel intervention with the potential to significantly improve perioperative outcomes. This trial will
provide the first evaluation of RIPC’s ability to reduce adverse clinical events following major vascular surgery.
Trial Registration: www.clinicaltrials.gov NCT02097186 Date Registered: 24 March 2014
Keywords: remote preconditioning, vascular surgery, perioperative complicationsBackground
Ischaemic preconditioning is a phenomenon whereby a
brief period of nonlethal ischaemia in a tissue renders it
resistant to the effects of a subsequent much longer
ischaemic insult. It was first described in the canine heart
[1]. Subsequent clinical trials showed that ischaemic pre-
conditioning reduced heart muscle damage following
coronary artery bypass grafting [2] and liver dysfunction
following hepatic resection [3]. Following cardiac surgery,
it is associated with a reduction in critical care stay,
arrhythmias and inotrope use [4]. However, ischaemic pre-
conditioning requires direct interference with the target
tissues’ blood supply, limiting its clinical utility. Further
experimental work suggested that brief ischaemia in one
tissue, such as the kidneys, could confer protection on dis-
tant organs such as the heart [5]. A similar effect was
observed after transient skeletal muscle ischaemia [6].
This effect is referred to as ‘preconditioning at a distance’
or ‘remote ischaemic preconditioning’ (RIPC).
Patients requiring major vascular surgery for end-stage
vascular disease constitute a high-risk surgical cohort. Peri-
operative complications such as myocardial infarction, cere-
brovascular accident, renal failure and death are common
[7,8]. Multiple potential mechanisms may lead to these
complications. For example, myocardial injury may result
from systemic hypotension leading to reduced flow across a
tight coronary artery stenosis or, alternatively, it may arise
due to acute occlusion when an unstable plaque ruptures.
Most strategies aimed at perioperative risk reduction target
a single potential mechanism. Thus, for example, beta-
blockade may prevent myocardial injury due to overwork,
but cannot prevent acute coronary occlusion. There is a re-
quirement for a simple, effective intervention that protects
tissues against injury via multiple different mechanisms. Re-
mote ischaemic preconditioning (RIPC) may be suitable.Proof-of-concept trials
To date, there have been five small trials of RIPC in pa-
tients undergoing major vascular surgery (Table 1). The
results were mixed. An apparent beneficial effect of
RIPC on renal function following open abdominal aortic
aneurysm (AAA) repair in one trial [9] could not be rep-
licated in a subsequent smaller study specifically
designed to evaluate renal injury [10]. However, RIPC
did reduce renal injury biomarkers following elective
endovascular aneurysm repair (EVAR) [11]. In carotid
endarterectomy patients, RIPC had no significant effect
on subclinical cerebral injury, as determined by saccadic
latency deteriorations [12]. However, this trial was ren-
dered underpowered by a high level of patient with-
drawals. More recently, a further trial conducted in
patients undergoing open AAA repair reported that
RIPC reduced markers of pulmonary and intestinal in-
jury [13]. A number of additional small trials have
assessed the potential value of RIPC in adult cardiac sur-
gery, again with mixed results [2,14]. Most of these small
phase 1 and 2a trials did not report clinical outcomes in
any detail, focusing appropriately on biomarkers. Re-
cently, a pooled analysis of some of these trials reported
a significant reduction in post-operative troponin levels
with RIPC [15]. Few of these studies reported clinical
outcomes for example, death, myocardial infarction etc.
Another recent meta-analysis examined the effect of
RIPC on major clinical complications among 2,200 pa-
tients who underwent major cardiovascular surgery [16].
This review found no significant clinical benefit with
RIPC, and the authors highlighted that this was likely to
be related to a lack of sufficient sample size along with
methodological heterogeneity in the individual studies.
At present, although exploratory studies are attractive,
there is a notable lack of data on the effect of RIPC on
Table 1 Summary of previous trials of remote ischaemic preconditioning (RIPC) in major vascular surgery
Trial reference Number randomised Operation type Main findings
Ali et al. Circulation [9] 82 Elective open AAA repair RIPC produced significant reductions in post-operative
troponin levels, myocardial infarctions and serum
creatinine levels
Walsh et al. Vasc Endovasc
Surgery [10]
40 Elective open AAA repair RIPC had no significant effect on post-operative renal
injury biomarkers.
Walsh et al. J Endovasc Ther [11] 40 Elective EVAR RIPC produced significant reductions in post-operative
biomarkers of renal injury
Walsh et al. Vasc Endovasc
Surgery [12]
70 Elective carotid endarterectomy RIPC had no significant effect on saccadic latency
deteriorations or biomarkers of cardiac injury
Li et al. Anesthesiology [13] 62 Elective open AAA repair RIPC produced significant reductions in biomarkers of
intestinal and pulmonary injury
Legend: Table summarising previous trials of remote ischaemic preconditioning in major vascular surgery.
AAA – abdominal aortic aneurysm; EVAR – endovascular aneurysm repair; RIPC – remote ischaemic preconditioning.
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are available, RIPC cannot achieve a place in routine
clinical practice.
Rationale
It is pertinent to continue to investigate RIPC in the set-
ting of major vascular surgery for several reasons. As
mentioned earlier, perioperative risk is high in this group
of patients and as such it is essential that risk reduction
strategies be developed and maximised. Myocardial con-
ditioning with RIPC seems especially attractive given the
encouraging preclinical and proof of concept studies and
given its benign risk profile. In contrast, other perio-
perative risk reduction strategies have limitations [17]:
preoperative cardiac risk assessment is theoretically at-
tractive but hard data on its efficacy are lacking [18];
pharmacological cardioprotection has largely been disap-
pointing [19] with the exception of beta blockade in high
risk groups [20]; prophylactic coronary revascularisation
was shown to be often ineffective [21-24] and is only
occasionally recommended [25,26]. Notably, the high
perioperative morbidity rates in vascular surgery also
confer a major practical advantage - as event rates are
high, studies are likely to achieve adequate power with
smaller sample sizes than would be necessary in lower
risk groups.
Ideally, a clinical trial of RIPC in major vascular surgery
would be powered to detect a significant reduction in
‘hard’ clinical endpoints (death, myocardial infarction etc.).
A primary composite end-point (death, myocardial infarc-
tion, cerebrovascular accident, mesenteric ischaemia, and
renal failure requiring renal replacement therapy) is
proposed as the primary efficacy end-point for a phase 3
trial. Some pilot data from 40 patients randomised at
University Hospital Limerick suggest that such an end-
point would occur in about 15% of patients. Assuming
that 15% develop this endpoint, a minimum of 726 pa-
tients would be required in each arm to demonstrate a re-
duction to 10% (alpha 0.05, beta 0.8).The proposed work builds on the previous trials con-
ducted by the chief investigator in this area, a programme
consistent with the ‘MRC Framework for the Design and
Evaluation of Complex Interventions to Improve Health’,
which suggests core phases to the development of health
interventions. This proposal describes the development
and piloting phases of the MRC framework. Conducting a
full-scale RCT, and economic evaluation, of remote pre-
conditioning ‘standard care’ in this population is likely to
require at least 1,500 participants and to be costly. As
there are uncertainties regarding rates of eligibility, con-
sent, participation in the intervention and retention for
follow-up - and regarding the feasibility/acceptability of
the intervention - this feasibility study is essential to
inform the design and conduct of a larger scale study.
Aims and objectives
This feasibility trial aims to address a number of key de-
sign uncertainties:
1. With the exception of Li et al. [13], the previous
vascular trials used the patient’s leg as the
preconditioning stimulus while the cardiac trials
almost always used the patient’s arm. The arm is
preferable due to the much lower incidence of upper
limb peripheral vascular disease. The use of arm
RIPC in major vascular surgery patients should be
assessed using a surrogate marker of efficacy in
advance of a full-scale trial.
2. Given the mixed results in the first four trials in
major vascular surgery, a phase 2B trial to further
evaluate potential efficacy using a surrogate marker
is required to justify phase 3 work. This will also
provide an accurate estimate of the likely effect size
that can be expected in any phase 3 trial.
3. Clinical trial capability in Ireland is underdeveloped
relative to other Western countries. An examination
of the feasibility of a large multicentre surgical trial
particularly with respect to recruitment, drop-off
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would be beneficial in advance of proceeding with a
phase 3 trial.
4. In order to evaluate the efficacy of RIPC in routine
clinical practice in a reasonable timeframe at
reasonable cost, we intend to use a composite primary
efficacy endpoint in any full trial. Data regarding the
incidence of this endpoint in major vascular surgery
patients are lacking. This feasibility trial will provide
robust data regarding this composite endpoint upon
which to base power calculations for a phase 3 trial,
should it appear justified from evaluation of the
surrogate efficacy marker.
The single main research question for the feasibility
trial, in terms of PICO (Population; Intervention; Com-
parator; Outcome) is as follows: ‘In adult patients un-
dergoing elective major vascular surgery, does RIPC
induced by brief arm ischaemia and reperfusion, when
compared to control, reduce troponin leakage in the first
3 days post-operatively?’. Whilst powered to address this
specific research question, this phase 2b trial will also
provide insight into the feasibility of running a larger,
phase 3 study, will provide data regarding the proposed
composite primary efficacy endpoint and will evaluate
the use of arm-generated as opposed to leg-generated
RIPC in major vascular surgery patients.
Methods/Design
Study design
This is a randomised controlled pilot trial of the effect of
RIPC induced by brief arm ischaemia and reperfusion
on troponin levels in the first 3 days post-operatively in
patients undergoing elective major vascular surgery.
Patients are randomised to receive RIPC or act as con-
trols. There is no sham intervention. The primary study
endpoint is determined at 3 days post-operatively. Sec-
ondary study endpoints are evaluated at 30 days and one
year post-operatively. Participant flow through the trial
is described in Figure 1.
Study setting
Patients undergoing scheduled major vascular surgery
will be screened for eligibility in five vascular surgery
units in the Republic of Ireland. Patients will receive
routine perioperative care according to the current
standard of care. During the study period, patients will
be discharged home or to continuing care facilities
within the geographic area.
Participants
Patients undergoing elective carotid endarterectomy,
open AAA repair, EVAR or surgical lower limb revascu-
larisation (suprainguinal or infrainguinal) will be eligiblefor inclusion. Patients will be excluded if any of the
following apply:
1. Pregnancy
2. Significant upper limb peripheral arterial disease
3. Previous history of upper limb deep vein thrombosis
4. Patients on glibenclamide or nicorandil (these
medications may interfere with RIPC)
5. Patients with an estimated pre-operative glomerular
filtration rate <30 mls/min/1.73 m2
6. Patients with a known history of myocarditis,
pericarditis or amyloidosis
7. Patients undergoing fenestrated or branched EVAR.
8. Patients with severe hepatic disease defined as an
international normalised ratio >2 in the absence of
systemic anticoagulation
9. Patients with severe respiratory disease (for the trial,
defined as patients requiring home oxygen therapy)
10. Patients previously enrolled in the trial representing
for a further procedure
11. Patients with prior axillary surgery who are thus
unsuitable for arm cuff inflation
Informed consent and ethical approval
In each centre, potentially eligible patients will be selected
from two patient groups: (1) outpatients awaiting major
vascular surgery or (2) inpatients awaiting major vascular
surgery. The process of obtaining informed consent will
be conducted in compliance with the principals of good
clinical practice and requirements of the approving
research ethics committee and other regulatory require-
ments as appropriate. Consent to enter the study must be
sought from each subject only after a full explanation has
been given and time allowed for consideration. Signed
subject consent will be obtained and a copy given to the
subject. It is a right of the subject to refuse to participate
or to withdraw at any time from the protocol without giv-
ing reasons and without prejudicing treatment. The trial
has been reviewed and received approval from the Re-
search Ethics Committees at University Hospital Limerick
(final approval 1 May 2014), Cork University Hospital
(ECM3 (j) 06/05/14), Waterford University Hospital (final
approval 29 July 2014), St. James’s Hospital (2014-01List/
05/19-02/2014-07 List25 (3), Beaumont Hospital (REC ref
(14/01) and Galway University Hospital (Ref 22/12).
Randomization, blinding and treatment allocation
Randomisation for the trial will be undertaken using a
web-based randomisation system administered by the
Health Research Board Clinical Research Facility Galway
(HRBCRFG). The use of third-party randomisation will
maintain allocation concealment. A unique trial number
will be assigned at the time of randomisation. On the
morning of surgery, patients will be randomised to one
Figure 1 Participant flow through the trial. AAA – abdominal aortic aneurysm; CEA – carotid endarterectomy; ECG –electrocardiography;
EVAR – endovascular abdominal aneurysm repair; PIL – patient information leaflet; RIPC – remote ischaemic preconditioning.
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Randomisation will be stratified by centre using ran-
domly selected blocks of 4, 6 and 8. In addition, each
centre will be stratified by procedure. The randomisa-
tion will be accessed by a designated member of the
research team at each site who will not be involved with
data collection.
Intervention
The intervention being tested is a simple intervention that
can be undertaken using existing equipment. Immediatelybefore the start of the operation, patients randomised to
the RIPC arm will have a standard, CE-approved tourni-
quet cuff placed around one upper limb. It will then be
inflated to a pressure of 200 mmHg for 5 minutes. For
patients with a systolic blood pressure >185 mmHg, the
cuff will be inflated to at least 15 mmHg above the
patient’s systolic blood pressure. The cuff will then be
deflated and the arm allowed to reperfuse for 5 minutes.
This will be repeated so that each patient receives a total
of four ischaemia-reperfusion cycles. There is no sham
intervention for those in the control arm.
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eous coronary interventions have generally used the arm
as the source of the RIPC stimulus. Four previous trials of
RIPC in major vascular surgery (Table 1) used the
patients’ legs to generate the stimulus. In these trials, four
patients in the RIPC arm developed post-operative critical
lower limb ischaemia requiring intervention. The presence
of known peripheral arterial disease also precluded the
enrolment of about 20% of otherwise eligible patients.
Given the success of upper limb RIPC in the cardiac and
percutaneous coronary intervention (PCI) trials, the upper
limb has been selected as the source for the RIPC stimulus
in Preconditioning SAVES. In common with the ERICCA
trialists [27], four cycles has been chosen in order to maxi-
mise the RIPC stimulus obtained and counteract three
potential confounding issues: (i) the lower skeletal muscle
bulk in the arm compared to the leg, (ii) the potential
resistance to RIPC in aging and diabetic patients and (iii)
the effect of variable volatile anaesthetic use.
There is a theoretical possibility that the RIPC stimu-
lus obtained from the upper limb will be insufficient to
produce a detectable effect due to the smaller skeletal
muscle bulk compared to the lower limb. An adaptive
trial design is therefore proposed, in which an interim
analysis will be conducted after randomisation of 200
patients. If there is no evidence of potential benefit at this
point, the stimulus will be adjusted to include three cycles
of 5 minutes lower limb ischaemia alternating with 5 mi-
nutes reperfusion. The first lower limb ischaemic episode
will commence as soon as the first upper limb ischemic
period ends, so that both limbs are being preconditioned
in parallel and no additional delay is introduced. If this
augmented stimulus is introduced, bilateral ankle-brachial
pressure indices <0.8 will be added to the exclusion
criteria. The decision to amend the protocol will be made
by the Trial Management Committee following advice
from the Data Monitoring Committee.
The trial will be undertaken at multiple sites. It is
intended to be a pragmatic clinical trial aiming to assess
the potential adjunctive value of RIPC in routine clinical
practice. Dedicated trial personnel will not be available
on all the sites for each patients operation. Conse-
quently, the SAVES trialists have elected not to include a
sham intervention in the protocol. To do so would ren-
der the trial impractical at many sites.
Study parameters
Baseline data
Patients will all have a full medical history taken and
clinical examination as part of their usual care. The fol-
lowing will be recorded:
1. Weight
2. Height3. Blood pressure
4. Heart rate
5. ECG
6. Gender
7. Ethnicity
8. Date of birth
9. Diabetes mellitus
10. Hypercholesterolaemia
11. Hypertension
12. Previous myocardial infarction
13. Previous coronary revascularisation
14. Previous stroke
15. Atrial fibrillation
16. Peripheral arterial disease
17. Smoking history
18. NYHA class
19. Medication at time of consent (aspirin, clopidogrel,
beta-blocker, calcium-channel antagonist, nitrates,
cholesterol-lowering agent, ACE inhibitor/A2
receptor antagonist, insulin, metformin,
sulphonylurea, or warfarin)
20. Serum creatinine and troponin.
Perioperative troponin
This will be assessed by measuring serum high-
sensitivity troponin I pre-operatively and at 24, 48 and
72 hours post-operatively (four samples per patient).
The samples will be analysed in the local laboratory at
each site, using local protocols.
Perioperative 12-lead electrocardiography
A 12-lead ECG is performed routinely as part of the
pre-operative assessment for major vascular surgery.
This will be used as the trial baseline ECG. Every patient
will undergo a second 12-lead ECG on the second post-
operative day. The pre- and post-operative ECGs to-
gether with the serum troponin levels will be reviewed
by the trial cardiologists to determine whether a peri-
operative silent myocardial infarction has occurred. The
reviewing cardiologists will be blinded to trial allocation.
Length of hospital/intensive therapy unit stay
The duration of hospital stay and intensive therapy unit
(ITU) stay have a major impact on health service re-
source utilisation, and are factors that can be influenced
by surgery.
Acute kidney injury score
The acute kidney injury (AKI) score will be calculated
over the first three perioperative days. Creatinine will be
measured daily as part of routine care. Urine volumes
will be calculated from the fluid balance charts main-
tained as part of usual care.
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On the morning of surgery, the patient will be rando-
mised to either the RIPC or control arm using a web-
based system. The following information on surgery will
be recorded for all patients: anaesthetic induction agents,
anaesthetic maintenance, duration of anaesthesia, type of
surgery, blood loss, maximum intra-operative heart rate,
minimum intra-operative systolic blood pressure. For
open AAA patients, the following additional data will be
recorded: infra-renal or suprarenal aortic clamp, cross-
clamp time, and mannitol use. For carotid endarterectomy
patients, shunt use and patch use will be recorded. For
endovascular aneurysm repair patients, screening time
and total contrast dose will be recorded.
Data at discharge
At discharge, duration of hospital stay and ITU stay will
be recorded.
Data at 1 year
General practitioners will be contacted 1 year following
randomisation to ascertain whether participants have
died or suffered myocardial infarction or cerebrovascular
accident. The national Hospital In-Patient Episode (HIPE)
database will be interrogated for hospital admissions and
patient status in the year since surgery.
Trial outcome measures
Primary efficacy endpoint
The trial is intended to pragmatically evaluate the poten-
tial of RIPC to improve clinical outcomes among pa-
tients undergoing major vascular surgery in routine
clinical practice. For the pilot trial, a surrogate marker of
efficacy will be used, namely serum troponin I levels.
The primary efficacy outcome will be a comparison of
the proportion of patients in each arm of the trial who
develop a raised serum troponin level in the first three
post-operative days. For patients with a baseline tropo-
nin level within the normal range, this outcome will be
considered positive when any subsequent troponin level
at 24, 48 or 72 hours post-operatively is above the upper
limit of normal. For patients with a baseline troponin
level that is above the normal range, this outcome will
be considered positive when any subsequent troponin
level at 24, 48 or 72 hours post-operatively is above the
baseline value. This is a dichotomous outcome for indi-
vidual patients.
Primary safety endpoint
The intervention under investigation carries a theoretical
risk of causing acute upper limb ischaemia or an upper
limb deep vein thrombosis. Such an event has not been
reported by any of the phase 1 and 2 trials of RIPC in
cardiac patients. In addition, there is a theoretical risk ofminor adverse events such as upper limb bruising. The
primary safety endpoint will again be a composite of
major life- or limb-threatening adverse events that could
be attributed to the preconditioning stimulus. The com-
ponents are:
1. Acute upper limb ischaemia
2. Acute upper limb deep vein thrombosis
The components of the primary safety endpoint are
defined as follows:
1. Acute upper limb ischaemia, which is defined as the
development of ischaemia in the arm used for the
preconditioning stimulus requiring systemic anti-
coagulation, radiological intervention or surgical
intervention; and
2. Acute upper limb deep vein thrombosis, which is
defined as the development of thrombus within the
subclavian, axillary or brachial vein confirmed in
duplex ultrasound and in the same arm as used for
the RIPC stimulus.
Secondary endpoints
Secondary endpoints are identified as follows:
1. The proposed composite primary efficacy endpoint
for a phase 3 trial (details below)
2. A comparison of the area under the curve of serial
troponin values between the two groups
3. Duration of post-operative hospital stay in days from
the date of surgery until the date of discharge to the
community
4. Duration of intensive care unit stay in days from the
date of surgery
5. Unplanned critical care unit admission defined as
any admission to a high dependency or intensive
care unit, which was not booked in advance of the
date of operation
6. Other post-operative complications (Table 2)
7. Acute kidney injury score in first three perioperative
days (Table 3)
8. Death within one year of surgery as determined by
contacting the patient’s general practitioner
9. Major adverse cardiac or cerebral event (myocardial
infarction, cardiac death, cerebrovascular accident)
within 1 year of surgery as determined by contacting
the patient’s general practitioner
Proposed composite Primary Efficacy Endpoint for
Phase 3
The proposed primary efficacy endpoint is a composite
Major Adverse Clinical Event (MACE). The selected end-
points represent common, life-threatening complications
Table 2 Definitions of other post-operative complications
Respiratory
failure
Unplanned initiation of assisted ventilation (CPAP or
IPPV)
Transient i
schaemic attack
New onset neurological deficit with lateralising signs,
which resolves within 24 hours without evidence of
cerebral bleeding or infarction on imaging and
confirmed by a stroke physician or neurologist
Vascular graft
occlusion
Occlusion of prosthetic or vein graft confirmed by
imaging within 30 days of surgery
Wound
infection
Erythema, purulent discharge, pyrexia, positive
pathogenic organism on culture
Chest infection Cough, dirty sputum, pyrexia, positive sputum culture
+/−pathogenic organism on sputum culture
Urine infection Pyrexia, leucocytosis, pathogenic organism on urine
culture
Abdominal
infection
Intra-abdominal abscess formation confirmed on CT
scan or at laparotomy
Other sepsis Sepsis due to any cause other than those listed above
for example, line infection
Prolonged ileus Absence of bowel function requiring the initiation of
nutritional support
Pulmonary
embolus
Confirmed radiologically or at autopsy
Deep vein
thrombosis
Confirmed radiologically or at autopsy
Limb ischaemia Compromised circulation in a limb requiring a
revascularisation procedure within 30 days of surgery
Major limb
amputation
Amputation of a limb due to unsalvageable critical
ischaemia within 30 days of surgery
Renal infarction New renal infarction on post-operative imaging
Renal
impairment
Post-operative ≥20% increase in serum creatinine
from pre-operative baseline
CPAP – continuous positive airway pressure; IPPV – intermittent positive
pressure ventilation.
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plays a significant role in these events, and thus, it is bio-
logically plausible that RIPC would reduce the frequency
of these events. The components are all strictly defined.
The occurrence of any of these events in a patient will be
classified as a MACE. The occurrence of multiple events
in a single patient will also be classified as a single MACETable 3 Acute kidney injury criteria
AKI grade Creatinine criteria Urine output criteria
1 Rise > 26.4 μmol/L or 150 to 200%
of baseline
<0.5 ml/kg/h for >6 h
2 Rise of 200 to 300% of baseline <0.5 ml/kg/h for >12 h
3 Increase of 300% or creatinine
>354 μmol/L with acute rise of
at least 44 μmol/L
<0.3 ml/kg/h for >24 h
or anuria for 12 h
Legend: Table summarising acute kidney injury criteria.
AKI – acute kidney injury.for the purposes of trial analysis. The components of the
primary efficacy endpoint are as follows:
1. Cardiovascular death
2. Myocardial infarction
3. Cerebrovascular accident
4. Renal failure requiring renal replacement therapy
5. Mesenteric ischaemia requiring intervention or
biopsy-proven ischaemic colitis
These components of the proposed primary efficacy
endpoint have been defined as follows:
1. Cardiovascular death, which is defined as death due
to a known cardiovascular cause or where the cause
of death is unknown that is, no other cause of death
is identified either from the medical history or at
post-mortem examination.
2. Myocardial infarction, which will include both
perioperative myocardial infarction and myocardial
infarction following vascular surgery. It will include
silent myocardial infarctions as determined by the
trial cardiologist upon examination of trial ECGs
and troponin results. The diagnosis of a myocardial
infarction will require the presence of at least two of
the following:
a. Characteristic ischaemic symptoms lasting at
least 20 minutes
b. Electrocardiographic changes including acute ST
elevation followed by the appearance of Q waves
or the loss of R waves, the development of new
left bundle branch block, new persistent T wave
inversion lasting at least 24 hours or new ST
segment depression persisting over 24 hours
c. Positive troponin T (>0.1 ng/ml) or troponin I
(>0.1 mg/ml) levels with a characteristic rise and
fall in levels
d. New-onset arrhythmia (ventricular or
supraventricular tachycardia or fibrillation) with
an associated rise in troponin levels
e. Alternatively, myocardial infarction will be
recorded if the patient develops sudden
unexpected cardiac death involving cardiac arrest
with symptoms suggestive of myocardial ischaemia
and accompanied by presumably new ST elevation
or new left bundle branch block and/or fresh
thrombus on coronary angiography and/or at
post-mortem, but death occurring before blood
samples could be obtained or at a time before the
appearance of cardiac troponin I or T in the blood.
3. Cerebrovascular accident, which is defined as new
onset neurological deficit, accompanied by evidence
of cerebral infarction or intra-cerebral haemorrhage
on CT scan, or confirmed at autopsy.
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which is defined as the initiation of any form of
renal replacement therapy for any reason within
30 days of major vascular surgery.
5. Mesenteric ischaemia requiring intervention or
biopsy-proven ischaemic colitis, which is defined as
small or large bowel ischaemia at laparotomy or
found at autopsy or histologically proven on biopsy.
Trial outcome assessment
The predefined outcomes will be recorded in an elec-
tronic case record form developed by the HRBCRFG.
Evaluation of perioperative myocardial infarction
Evaluation of pre- and post-operative electrocardiograms
and troponin levels for evidence of perioperative silent
myocardial infarction will be undertaken in batches by
the trial cardiologist, Dr Faisal Sharif. Dr Sharif will be
blinded to the trial allocation of each participant.
Evaluation of other outcomes
The development of the remaining outcomes will be de-
termined by a trial research nurse in the Dublin site and
by research fellows in the remaining three non-Dublin
sites. The individuals assessing these primary and sec-
ondary outcomes will be blinded to the trial allocation of
the patients, in order to minimise potential sources of
bias.
Evaluation of acceptability and barriers to
implementation
Whilst RIPC is simple to induce and inexpensive, it does
add to the burden of clinical staff in advance of major
vascular surgery. Perceptions that the intervention is
onerous will significantly impede adoption into routine
practice should a clinical benefit be demonstrated. It
may also significantly hinder recruitment in any phase 3
trial, as reluctance to complete the preconditioning
protocol may result in numerous protocol breaches in
the intervention arm. For patients, particularly those
undergoing regional anaesthesia rather than general, the
intervention may be burdensome and uncomfortable,
again negatively impacting upon likely adoption into
routine practice.
In order to explore these potential issues in advance of
any full-scale trial, the feasibility trial will include a qua-
litative evaluation of acceptability to both patients and
clinical staff together with a qualitative evaluation of any
perceived barriers to implementation. These insights
may be of value in the subsequent design of a full-
scale trial and may help adoption of RIPC in routine
practice should the intervention prove clinically and
economically-efficacious.Healthcare professionals at participating practices will
be asked to complete a self-administered questionnaire
at the end of the study period. The questionnaire will
elicit data on profession and practice details, their per-
ceived experience of trial involvement, and open-ended
questions to elicit information regarding attitudes to trial
involvement, willingness to recruit participants, difficul-
ties that arose during the trial and potential barriers to
further research or routine clinical use of the trial
intervention.
A convenience sample of 40 patients (10 from each
site) will be contacted following their surgery to conduct
a brief interview. This will again involve the use of open-
ended questions in order to elicit information regarding
patients’ attitudes towards the intervention and per-
ceived barriers to implementation.
Sample size
Currently, the projected sample size for a full phase 3
trial using the composite clinical endpoint mentioned
above is 1,500 patients in total. This would provide suffi-
cient power to detect a reduction in the proportion of
patients sustaining the endpoint from 15% to 10% (alpha
0.05, beta 0.8). The assumed 15% figure in the control
arm is based upon data from a sample of only 40 pa-
tients randomised at University Hospital Limerick. Be-
fore proceeding with a full-scale trial, and in accordance
with the MRC framework for the evaluation of complex
interventions, it would be preferable to (i) explore the
feasibility of randomising a significant number of sur-
gical patients in the Irish healthcare system context,
(ii) undertake further work using a surrogate marker of
efficacy to more robustly evaluate the apparent protec-
tive effect of RIPC in major vascular patients, (iii) use
such a surrogate marker to evaluate the likely effect size
of RIPC, and (iv) confirm that arm-induced RIPC is pro-
tective in major vascular patients.
In order to fully evaluate objectives (ii) to (iv) above, the
feasibility trial design utilises troponin-positive events as
the primary outcome. The sample size calculation for the
pilot trial is based upon recently published data regarding
post-operative troponin-positive events following major
vascular surgery. In a cohort of 337 patients undergoing a
mix of major vascular procedures (open and endovascular
aneurysm repair, carotid endarterectomy or surgical lower
limb revascularisation), 135 (40%) developed a post-
operative troponin level in excess of the upper limit of
normal. At one year post-surgery, patients with a troponin
positive event, that is, those with a level in excess of the
upper limit of normal, were more likely to have died [28].
The planned patient cohort for this feasibility trial is very
similar to that reported above. Moreover, analysis of pre-
liminary data from 40 patients randomised at University
Hospital Limerick found that 19/40 patients developed a
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dence of troponin-positive events, 166 patients would be
required in each arm to demonstrate a reduction to 25%
(alpha 0.05, beta 0.8). To account for dropouts and losses
to follow-up, we plan to recruit 200 patients to each arm
of the trial. This sample will also provide robust data re-
garding the likely incidence of the proposed composite pri-
mary efficacy endpoint for a phase 3 trial. At 25% of the
proposed full trial recruitment, the investigators feel it is
sufficiently large to allow adequate testing of trial proce-
dures and compliance at multiple sites in line with object-
ive (i) above.
Statistical analysis plan
The statistical analysis plan has been developed in con-
junction with the HRBCRF Galway. The statisticians will
be blinded to the trial allocation for all analyses, with
the two trial arms being labelled A and B.
Interim analysis
An interim analysis will be undertaken once 200 patients
have been recruited and 30-day follow-up accrued. This
analysis will be undertaken by Dr John Newell, HRBCRF
Galway. The interim analysis will be reviewed by the Data
Monitoring Committee (Dr John Newell, Prof Martin
O’Donnell, and Professor Walter Cullen) and used to
provide a recommendation to the Trial Management
Committee as to whether the adaptive clauses in the trial
design should be invoked.
Final analysis
Once the trial has closed, a final analysis of the data will
be conducted by Dr Newell, the trial biostatistician. The
trial arms will be labelled A and B, to maintain blinding.
Baseline characteristics will be compared between the
trial arms to evaluate the efficacy of randomisation. The
proportions of patients with troponin positive events,
components of the composite clinical outcome, primary
safety endpoints, troponin levels, unplanned critical care
admission and other post-operative complications will
be compared between the trial arms. Hospital stay and
intensive care unit stay will also be compared between
the two trial arms. One-year survival and cardiac- and
cerebral-event free survival will be compared. These
results will all be presented in the final trial report.
Subgroup analyses
Experimental data suggest that the protective effect of
RIPC may be attenuated in diabetic patients. This trial
provides an opportunity to evaluate the relationship be-
tween RIPC and diabetes in clinical practice. There will
be two components to this analysis. In the diabetic sub-
group, the proportion of patients suffering a troponin-
positive event will be compared between those patientswho receive RIPC and patients who are controls. In
addition, the proportion of patients suffering a troponin-
positive event will be compared between diabetic RIPC
patients and non-diabetic RIPC patients, in order to de-
termine whether the effect size of RIPC differs signifi-
cantly in diabetic patients. These data will inform
subsequent design of a phase 3 trial, should it appear
justified.
There have also been suggestions that RIPC is attenu-
ated in older patients. Again, this trial provides an oppor-
tunity to investigate this potential relationship further.
Proportions of the patients sustaining a troponin-positive
event will be compared between patients aged ≥80 years
at randomisation and patients aged <80 years at random-
isation. The proportion with a troponin positive event will
also be compared between RIPC and control patients in
the ≥80 subgroup. A between group analysis will compare
the proportions of troponin positive events between RIPC
patients in the ≥80 and <80 groups. These data will again
inform subsequent design of a phase 3 trial, should it
appear justified.
Health economics
Within trial economic analysis of direct resource costs
and health outcomes will be conducted on an intention
to treat basis. A health service perspective will be
adopted for measuring and valuing health care utilisa-
tion. Using a case-mix approach, we will estimate acute
hospital one-year cumulative costs based on the index
episode and subsequent events defined in the MACE
composite clinical endpoint. No discounting of direct re-
source costs will be conducted as the time horizon will
be limited to one year for within trial analysis.
Survival times will be adjusted using preference or
utility weights assigned to each of the events in the
MACE to calculate quality adjusted life years (QALYs).
The primary treatment effect in the economic analysis
will be estimated using an individual level regression
model for average (mean) incremental costs and incre-
mental QALYs. The model will consider the joint distri-
bution of costs and QALYs using a general specification
that will allow for different parametric and conditional
distributions. We also plan to use a Bayesian model with
minimally informative priors for means and large vari-
ances, following the general framework outlined by Baio
[29]. Model parameter uncertainty will be addressed
using probabilistic sensitivity analysis summarised using
the cost-effectiveness acceptability curve. The heterogen-
eity of economic treatment effects will be assessed using
pre-defined strata on age and people with diabetes.
Longer run modelling will estimate the distribution of
costs and QALYs calculated over the expected patient
lifetimes. A microsimulation model will be calibrated
using information gained from the within trial analysis
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(i) trials and observational studies reporting longer run
costs, survival and health related quality of life following
RIPC and (ii) expert beliefs on the distributions of
parameters where information is less readily available.
The structural uncertainty in the long run model will be
addressed using model averaging methods [30].
Qualitative data analysis
Each interview will be transcribed verbatim, following
which, the transcript will be reviewed by the researchers
for accuracy. Each interview will be ‘openly coded’ (to
allow development of categories of concepts, without
making any prior assumptions). The researcher will ana-
lyse half the interviews first to identify common codes
for each group of respondents. These coded transcripts
will be reviewed by a second researcher to ensure the in-
terviews are coded correctly and consistently and the
codes identified by the researcher were the same as those
identified by the expert. The second half of the transcripts
will be consequently added to the analysis one-by-one
allowing for the monitoring of data saturation.
For the purpose of this research, thematic analysis will
be used to analyse qualitative data. This approach has
many benefits for studies such as this, which are inter-
pretive in nature, as it is a ‘method for identifying, ana-
lysing and reporting patterns (themes) within data’ [31].
The process of thematic analysis is concerned with the
basic to advanced encoding of data, which are subse-
quently developed to themes. Themes are described as
‘patterns found in the information’ that can be devel-
oped in an inductive manner from raw information but
also deductively from prior/existing research and know-
ledge. This flexible approach can also be seen in how
themes identified at one level can help the researcher
describe their observations and at a more advanced level
allow the researcher to interpret aspects of the phe-
nomenon under study [31].
Qualitative data analysis will be systematic and orga-
nised in order to easily locate information within the
data set when tracing results, providing examples in
context [31]. The qualitative research software Nvivo v8
will be used to facilitate the coding of this data. Such
research software allows the researcher to manage, shape
and make sense of unstructured information; it also
facilitates the complex organisation and retrieval of data
(www.qsrinternational.com). The analysis will follow a
‘5-Step Analysis’ approach whereby data is reviewed,
examined, coded, themes generated and defined [31]. To
achieve validity in the coding/analysis of data, two
reviewers will code data independently and inter-rater
reliability measures will be computed based on this cod-
ing. Coding consistency will be maintained throughout
the coding process and will be reviewed by regularmeetings between researchers and principal investigator.
The findings will be compared with other study findings
(validity and credibility). The researchers will present the
findings to participants to determine if the study find-
ings reflect their experience of the topic under study
(member checking). Illustrative quotes will be used to
emphasise points made by the participants.
Dissemination plan
It is the intention of the trial team to disseminate the
results of the trial as widely as possible. This is likely to
be through publication in a peer-reviewed vascular sur-
gery journal, and also via presentations at National and
International Cardiology Conferences. Publication will
be in accordance with the CONSORT guidelines. The
trial will be registered before randomisation commences.
The results will be submitted for presentation at major
vascular surgery conferences. It is anticipated that the
trial manuscript will be submitted for publication by
2016. The paper will be attributed to the Precondition-
ing SAVES Group. Individual clinicians involved in the
trial will be listed by centre at the end of the trial.
Discussion
Strengths
This is the first trial seeking to evaluate the role of re-
mote preconditioning as a protective adjunct in a typical
population of elective major vascular surgery patients. It
will have sufficient power to detect a reduction in post-
operative troponin-positive events, which are known to
adversely affect survival following major vascular sur-
gery. The inclusion of a qualitative evaluation of staff
and patient experiences with RIPC will also provide for-
mal data on the intervention’s acceptability. The adaptive
design allows for evaluation of a combined arm/leg RIPC
stimulus should it appear that the arm stimulus alone is
insufficient at the interim analysis stage.
Weaknesses
Ideally, patients randomized to the control arm would
receive a sham intervention. Trial staffing is minimal. In
the absence of dedicated trial staff at each site to under-
take the intervention, the inclusion of a sham interven-
tion was felt to be excessively onerous and likely to
adversely impact on trial participation and enrolment by
the surgical teams.
Trial status
Recruitment for the trial began 1 June 2014.
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